【作者】 郝颂华；

【导师】 杨玲竹；

【作者基本信息】 郑州大学 ， 妇产科学， 2010， 硕士

【摘要】 目的探讨参麦注射液联合紫杉醇、顺铂(TP方案)化疗与单纯TP方案化疗对晚期卵巢癌的疗效、不良反应及免疫功能的影响。方法将60例晚期卵巢癌患者分为参麦组和对照组,两组均采用TP方案化疗(紫杉醇135mg/m2,顺铂75mg/m2),每3-4周为一个疗程,共六个疗程。化疗前12h及6h各口服地塞米松20mg；化疗前30min给予苯海拉明50mg及雷尼替丁50mg静注。对照组仅接受TP化疗,参麦组在化疗前3天开始使用参麦注射液50ml加入5%葡萄糖250ml中,静脉滴注,1次/日,连续10天；第4天开始实施相应的化疗方案。观察化疗前后T淋巴细胞亚群的变化,临床有效率及毒副作用。结果1.参麦组治疗前后CD3、CD4、CD8无明显改变(P>0.05)；对照组治疗后CD3、CD4、CD8较治疗前明显下降,且均低于参麦组治疗后(P<0.05)。2.参麦组有效率70.0%与对照组有效率63.3%比较,差异无统计学意义(P>0.05)。3. Kamofsky评分,参麦组治疗前78.6±4.5与治疗后70.7±7.1比较无差异(P>0.05)；对照组治疗后61.2±3.7明显低于治疗前的77.6±5.0(P<0.05),对照组治疗后与参麦组治疗后比较有统计学差异(P<0.05)。4.两组患者比较,白细胞减少、血小板减少、恶心、呕吐毒副作用发生率参麦组明显低于对照组(P<0.05)。对肝、肾功能两组均无明显影响。结论参麦注射液联合TP方案治疗晚期卵巢癌,降低了TP化疗方案对免疫功能的影响和对胃肠道的不良反应,具有较高的临床应用价值。更多还原

【Abstract】 ObjectiveTo research the curative effect and side effect of Shenmai injection plus TP chems for treating late-stage ovarian cancer.MethodsThe patients of 60 ovarian cancer divided equally into Shenmai group and control group. All patients were given TP chems keep on six times of therapy. Before the chems, the patients were taken dexamethasone 20 mg orally, intravenous injection of benzhydramine 50 mg and ranitidine 50 mg. Before the three days of chems, the Shenmai group was given Shenmai injection 50ml, continued 10 days, and gave chems at the fourth day. Before and after treatment, T-cell subpopulation, clinical effects and side effects were observed.Results1. Before and after treatment, The CD3, CD4 and CD8 of Shenmai group had no significant change (P>0.05). The control group had significantly decrease (P<0.05).2. The effective rate in Shenmai group was 70.0%, compared with the control group 63.3% had no statistical significance (P>0.05).3. The score of Karnofsky, The before and after of treatment, the Shenmai group had no significant change (P>0.05). The pretherapy of control group 77.6±5.0 had descent compared with post-treatment 61.2±3.7 (P<0.05).4. The incidence rate of side effects had significant statistical significance (P<0.05) between two groups. ConclusionShenmai injection combined with TP is effective in treatment of patients with late-stage ovarian cancer, and deserve to generalization of clinical application.更多还原